Novartis AG Loss Form

Company: Novartis AG

Ticker: () NVS

See If You Qualify For Monetary Reward

Contact Information

Required Field

Levi & Korsinsky, LLP does not share your information with others. There is no cost or obligation for you to submit.

Please Upload related files below

Add Transactions

Purchases

1.

Common Stock
Preferred Stock
Bonds
Calls
Puts

Additional Purchases

Sales

1.

Common Stock
Preferred Stock
Bonds
Calls
Puts

Additional Sales

Please input at least 1 transaction or press "skip for now" button below

Please fill in all the fields for your transaction or press "skip for now" button below

Fill in below.

Certification of Plaintiff Pursuant to Federal Securities Laws

I, duly certify and say, as to the claims asserted under the federal securities laws, that:

1. I have reviewed a complaint filed in the action.

2. I did not purchase the security that is the subject of this action at the direction of plaintiff's counsel or in order to participate in this action.

3. I am willing to serve as a representative party on behalf of the class, including providing testimony at deposition and trial, if necessary.

4. My transaction(s) in Novartis AG which are the subject of this litigation during the class period set forth in the complaint are set forth in the chart attached hereto.

5. Within the last 3 years,

I have not sought to serve nor have I served as a class representative in any federal securities fraud case.
I have sought to serve as a class representative in

6. I will not accept any payment for serving as a representative party on behalf of the class beyond the Plaintiff's pro rata share of any recovery, except as ordered or approved by the court, including any award for reasonable costs and expenses (including lost wages) directly relating to the representation of the class.

Are you US Citizen?

Yes. I certify under penalty of perjury that the foregoing is true and correct. Executed this
No. I certify under penalty of perjury under the laws of the United States of America that the foregoing is true and correct. Executed this

Clear

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

By your signature above, you confirm that have retained Levi & Korsinsky, LLP and agree to serve as a lead plaintiff in an action against Novartis AG. We agree to advance all expenses in the litigation, which means that you are not liable to pay any of the expenses of the lawsuit, whether attorneys' fees or costs. Regardless of the result, we will never ask you to directly pay for any attorneys' fees or costs. Should we obtain a favorable result, we may ask the court to award us compensation and reimbursement of expenses to be paid by the defendants or as a portion of any benefit, but we will never ask you to directly pay any of the costs of this litigation. As our client, you are entitled to direct the litigation in any way you deem proper, and may at any time order us to dismiss the case. Should you choose to do so, we will never ask you to reimburse us directly for any legal fees or expenses. You further agree to cooperate in our prosecuting the action, including providing relevant documents and deposition testimony, if necessary. During the course of this litigation, we may employ and/or work with other law firms to prosecute your case. If the Court does not appoint you as a lead plaintiff or you are not added as a plaintiff to a complaint filed in the action, then this retainer agreement and Levi & Korsinsky, LLP's representation of you will terminate automatically.

I have reviewed the complaint linked in paragraph 1

Looking for more?

Thank you for completing your submission. If our attorneys find you are a viable candidate for lead plaintiff they will reach out regarding the next steps.

All shareholders who submit will receive updates regarding the case.

Investigation Details

On August 6, 2019, the United States Food and Drug Administration (“FDA”) issued a statement revealing data manipulation in connection with the May 2019 approval of Novartis’ gene therapy drug, Zolgensma. According the the statement, AveXis Inc., a subsidiary of Novartis and the product’s manufacturer, “became aware of the issue of the data manipulation that created inaccuracies in their [biologics license application] before the FDA approved the product, yet did not inform the FDA until after the product was approved”. The FDA’s continuing investigation may lead to penalties for Novartis, and the Company’s share price has already fallen significantly.